Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

Based on their findings, the researchers suggest the integration of automated measures to identify interventricular septal (IVS) flattening in these patients.

A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.

Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.

Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help improve the landscape.

Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey.

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.